<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00004022</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000067241</org_study_id>
    <secondary_id>P30CA022453</secondary_id>
    <secondary_id>WSU-C-1403-ME</secondary_id>
    <secondary_id>NCI-G99-1565</secondary_id>
    <nct_id>NCT00004022</nct_id>
  </id_info>
  <brief_title>Biological Therapy Following Surgery in Treating Patients With Stage III or Stage IV Melanoma</brief_title>
  <official_title>Immunotherapy for Malignant Melanoma - Phase II Trial of Autologous Cancer Antigen Specific Immunotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Barbara Ann Karmanos Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Barbara Ann Karmanos Cancer Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Biological therapies use different ways to stimulate the immune system and stop&#xD;
      cancer cells from growing. Combining different types of biological therapies may kill more&#xD;
      tumor cells.&#xD;
&#xD;
      PURPOSE: Phase II trial to study the effectiveness of biological therapy following surgery in&#xD;
      treating patients who have stage III or stage IV melanoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Evaluate the efficacy of immunotherapy with irradiated autologous tumor cell vaccine and&#xD;
           sargramostim (GM-CSF) followed by monoclonal antibody OKT3- activated T lymphocytes and&#xD;
           interleukin-2 in combination with surgery in terms of response rate in patients with&#xD;
           stage III or IV malignant melanoma.&#xD;
&#xD;
        -  Determine the immunogenicity of malignant melanoma in this patient population.&#xD;
&#xD;
      OUTLINE: Patients are stratified according to extent of disease, extent of antigen specific&#xD;
      response to vaccination, performance status (0 vs 1), prior therapy (yes vs no), and gender.&#xD;
&#xD;
      Patients undergo surgical resection of tumor on week 1. Within 1-2 weeks of surgery, patients&#xD;
      are vaccinated with irradiated autologous tumor cells and sargramostim (GM-CSF), then receive&#xD;
      GM-CSF alone intradermally at vaccination sites daily for 4 days. Patients are revaccinated 2&#xD;
      weeks later.&#xD;
&#xD;
      Patients undergo peripheral blood mononuclear cell collection two weeks after the second&#xD;
      vaccination. Peripheral blood mononuclear cells are stimulated with anti-CD3 monoclonal&#xD;
      antibody (OKT3) and interleukin-2, producing activated T lymphocytes. The activated T&#xD;
      lymphocytes are infused IV over 1-6 hours followed by 5 doses of interleukin-2 IV every other&#xD;
      day over 10 days. Treatment continues in the absence of disease progression or unacceptable&#xD;
      toxicity.&#xD;
&#xD;
      Patients may receive one additional course of immunotherapy as above.&#xD;
&#xD;
      Patients are followed every 3 months for 2 years, then every 6 months thereafter.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 60 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 1997</start_date>
  <completion_date type="Actual">January 2004</completion_date>
  <primary_completion_date type="Actual">January 2004</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>Melanoma (Skin)</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>aldesleukin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>autologous tumor cell vaccine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>muromonab-CD3</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>therapeutic autologous lymphocytes</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>surgical procedure</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically proven stage III or IV malignant melanoma&#xD;
&#xD;
          -  Resectable disease&#xD;
&#xD;
          -  At least 50,000,000 viable cells obtained from surgical specimen for use in the&#xD;
             immunization part of this study&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  SWOG 0 or 1&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  At least 6 months&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  Granulocyte count at least 1,500/mm^3&#xD;
&#xD;
          -  Platelet count at least lower limit of normal&#xD;
&#xD;
          -  No active or recent uncontrolled bleeding&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Bilirubin normal&#xD;
&#xD;
          -  SGOT no greater than 2 times upper limit of normal (ULN) (no greater than 5 times ULN&#xD;
             if liver metastases present)&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Creatinine normal&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  Negative stool guaiac&#xD;
&#xD;
          -  No impaired immunity&#xD;
&#xD;
          -  No uncontrolled diabetes&#xD;
&#xD;
          -  No active uncontrolled infections&#xD;
&#xD;
          -  No other serious disease&#xD;
&#xD;
          -  No other malignancies within the past 5 years except curatively treated basal or&#xD;
             squamous cell skin cancer or carcinoma in situ of the cervix&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  No concurrent chemotherapy&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  At least 2 weeks since prior therapy and recovered&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Roy D. Baynes, MD, PhD, FACP</last_name>
    <role>Study Chair</role>
    <affiliation>Barbara Ann Karmanos Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Barbara Ann Karmanos Cancer Institute</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2013</verification_date>
  <study_first_submitted>November 1, 1999</study_first_submitted>
  <study_first_submitted_qc>September 10, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 13, 2004</study_first_posted>
  <last_update_submitted>April 3, 2013</last_update_submitted>
  <last_update_submitted_qc>April 3, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 5, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage III melanoma</keyword>
  <keyword>stage IV melanoma</keyword>
  <keyword>recurrent melanoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aldesleukin</mesh_term>
    <mesh_term>Muromonab-CD3</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

